Cancer name Lymphoma
Cancer Type DLBC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment SR0987
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature PD-1
Official Symbol PDCD1
Mode of action TRAN_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Stimulation of EL4 cells led to an increasein the expression of all three genes, and when coupled with treatment with the synthetic RORγt agonist SR0987 a further increase in expression of IL17 was observed, suggesting that there was in induction of T cell activation. Surprisingly and unexpectedly, treatment with SR0987 led to a decrease inexpression of PD-1. Compound treatment did not impact the expression of granzyme B. Combined, these results suggest that treatment with SR0987 may enhance protective immunity by regulating expression of IL17 and PD-1 while maintaining the cytotoxic ability of these cells.
PMID 26785144
Title Synthetic RORγt Agonists Enhance Protective Immunity.